India is making significant strides in its fight against tuberculosis (TB) by introducing advanced, indigenously developed TB diagnostic tests. The Indian Council of Medical Research (ICMR) has recently validated two innovative tools from Huwel Lifesciences: the Quantiplus MTB FAST detection kit and the UniAMP MTB Nucleic Acid Test Card. These new technologies promise to transform TB detection, making it faster, more affordable, and broadly accessible across the nation.
Revolutionizing TB Detection in India
Eliminating tuberculosis critically depends on early, accurate, and universal detection to facilitate timely treatment and reduce community transmission. Therefore, these Made-in-India advancements represent a major boost to the country’s testing capabilities. Dr. Nivedita Gupta, Head of the Communicable Diseases Division at ICMR, emphasizes that this rigorous validation process ensures innovative TB diagnostics are quickly tested, reflecting India’s dedication to indigenous research and closing early detection gaps.
Quantiplus MTB FAST: An Open-System Solution for TB Diagnostic Tests
The Quantiplus MTB FAST detection kit, developed by Huwel Lifesciences in Telangana, stands out as a groundbreaking open-system RT-PCR (Reverse Transcription Polymerase Chain Reaction) assay. Importantly, this kit is validated for lung TB detection and can operate on any existing PCR machine, unlike proprietary platforms. This flexibility means that laboratories throughout India, including those without specialized “closed” equipment, can readily expand rapid molecular TB testing using their standard PCR machines.
Moreover, the Quantiplus kit offers an extraction-free protocol, simplifying the testing process and providing results in under 60 minutes. It can efficiently process up to 96 samples simultaneously, significantly enhancing testing capacity. Experts estimate that this innovation can reduce TB testing costs by as much as one-fifth, empowering public sector labs to scale up testing without substantial investments in new machinery. Consequently, this makes TB diagnostic tests more affordable and accessible.
UniAMP MTB: Patient-Friendly Diagnostics with Tongue Swabs
The second indigenously developed tool validated by ICMR is the UniAMP MTB Nucleic Acid Test Card, also from Huwel Lifesciences. This innovation marks a milestone in patient-friendly diagnostics because it allows for testing using non-invasive tongue swabs instead of traditional, often difficult-to-obtain sputum samples. This method significantly eases the process, especially for vulnerable populations such as children and the elderly.
Furthermore, tongue swabs offer a comfortable and non-invasive alternative, opening possibilities for doorstep TB diagnosis. This could greatly aid large-scale community screening efforts and broaden access to life-saving TB care across India. These point-of-care diagnostics represent a significant step towards decentralizing testing and enhancing patient comfort.
Broader Impact on India’s TB Elimination Mission
These new tools build upon and enhance existing technologies like Truenat and PathoDetect, which already decentralize high-precision Nucleic Acid Amplification Tests (NAAT). This continuous innovation helps reduce delays in diagnosis and facilitates effective treatment for both drug-sensitive and drug-resistant TB.
The validation of these advancements underscores the Indian government’s commitment to fostering a robust domestic scientific ecosystem. If deployed at scale, these Made-in-India TB diagnostic tests have the potential to profoundly transform TB screening, making it quicker, more economical, and far more accessible to those who need it most, thereby accelerating India’s journey towards TB elimination.
Frequently Asked Questions
Q1: What are the primary benefits of the new TB diagnostic tests?
The newly validated TB diagnostic tests offer several key benefits, including faster results, significantly reduced costs (up to one-fifth of current prices), and increased accessibility through open-system PCR compatibility and non-invasive sample collection methods like tongue swabs.
Q2: How does the Quantiplus MTB FAST kit improve TB testing?
The Quantiplus MTB FAST kit is an open-system RT-PCR assay that can run on any standard PCR machine, removing the need for specialized proprietary equipment. It processes up to 96 samples simultaneously with an extraction-free protocol, making testing quicker and more cost-effective for laboratories.
Q3: Why is the UniAMP MTB Nucleic Acid Test Card considered patient-friendly?
The UniAMP MTB Nucleic Acid Test Card uses non-invasive tongue swabs for sample collection, which is much easier and more comfortable for patients, especially children and the elderly, compared to traditional sputum samples. This method also enables potential doorstep testing and wider community screening.
References
- India’s TB fight gets a boost: New Made-in-India diagnostic tests cut cost &time – ETHealthworld
- Huwel Lifesciences. Quantiplus® MTB & MDR TB Detection Kits.
- Huwel Lifesciences. Huwel MTB FAST RT-PCR Kit: Open RT-PCR Kit for Tuberculosis (TB) Detection.
- Huwel Lifesciences. UniAmp, a palm-sized NAT device for rapid diagnosis of multiple diseases & infections.
- ICMR Strengthens Strategies for Faster & More Accurate Tuberculosis Diagnostics.
- Innovative Tools in Tuberculosis Screening: ICMR’s Latest Breakthroughs.
- “Made-in-India open-system RT-PCR kit promises to make TB screening faster & cheaper. Here’s how – ThePrint.” ThePrint.
- “Made-in-India TB diagnostic tests validated by ICMR; offer cheaper, faster detection | Health News.” Hindustan Times.
- “Made-in-India TB diagnostic tests validated by ICMR; offer cheaper, faster detection.” PTI.
- Huwel Lifesciences. Test your patients at your clinic in minutes – UniAmp NAT Device.
- ICMR. MTB/MDR-TB detection kits prospectively validated and approved by ICMR.
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.